Site 'Main' Navigation:

There are no approved drugs that prevent progression to liver cirrhosis.

We're working to change that.

Events and
Presentations

March 8, 2019 4:30 PM EST : Conatus Pharmaceuticals Fourth Quarter 2018 Financial Results
Open Webcast
March 08

View All

Latest News
from Conatus

Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
March 13

More News

Our
Programs

Emricasan is a first-in-class, orally active caspase inhibitor designed to reduce the activity of ...

Learn More

Liver cirrhosis kills 32,000 Americans each year.

The only "cure" is a transplant.

Learn More

By 2020, the leading cause of liver transplants is expected to be NASH.

We're moving toward
registration with an
initial focus on
NASH cirrhosis.

Registration Plans